Taking Charge of Charge Variants

A principal reason for why the manufacture of biologics is difficult is the structural complexity of the recombinant glycoproteins that are being produced.  As biologics production moves from research and…

0 Comments

CAR-T cells: Beyond CD19

CAR-T cells are a new and exciting drug class in which treatment involves the use of transformed immune cells for cancer therapy. A patient’s T- cells are removed, transduced and expanded…

0 Comments
Close Menu